BRAF and colorectal carcinoma: The synergistic effects of everolimus (RAD) and SN38 were assessed in CRC cell lines, HT29 (BRAF mt; PIK3CA mt; p53 mt), HCT116 (KRAS mt, PIK3CA mt), HCT8 (KRAS mt) and LS180 (KRAS mt; PIK3CA mt).